Ayala Pharmaceuticals (AYLA) CEO Roni Mamluk – Presentation from NobleCon17
Ayala Pharmaceuticals CEO Roni Mamluk’s presentation from NobleCon17, January 2021. Following a formal presentation, Roni is joined by Noble Capital Markets Senior Research Analyst Ahu Demir, PhD for a Q&A session, featuring questions submitted by the NobleCon live audience.
More information on Ayala Pharmaceuticals, including equity research, recent news, and advanced market data is available (at no cost) at https://www.channelchek.com/company/AYLA
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.
-
Category
No comments found